कंपनी का अवलोकन
Firefly Neuroscience, Inc. operates within the technology sector, specifically focusing on the software application industry, where it delivers neuroscientific solutions aimed at enhancing brain health outcomes for patients suffering from mental illnesses and neurological disorders. The company's core offering, Brain Network Analytics, is a specialized software platform that concentrates on diagnostic capabilities for these complex medical conditions. As of the latest available data, the enterprise holds a market capitalization of $26.87M, which places it in the category of a small-cap company with a relatively modest valuation in the broader financial landscape. Its annual revenue stands at $1.14M, a figure that, combined with an N/A employee count, suggests a business in a developmental or early-stage expansion phase where capital allocation is heavily weighted toward product development rather than large-scale workforce deployment. The market cap and revenue metrics collectively indicate that Firefly Neuroscience is a niche player seeking to establish market penetration and operational scale within the competitive medical technology and artificial intelligence domain.
वित्तीय स्वास्थ्य
The company reported a revenue of $1.14M over the trailing twelve months, yet it recorded a net income of -$24,531,000 and an EBITDA of -$8,464,000, revealing a significant divergence where operating expenses substantially exceed revenue generation. This gap between positive revenue and negative net income highlights a cost structure characterized by high burn rates typical of R-intensive biotech or AI firms that have not yet achieved commercial profitability. Free cash flow stands at -$6,578,250, indicating that the company is currently spending more cash on operations and capital expenditures than it is generating from its activities, which limits immediate financial flexibility but is often a strategic necessity for growth-stage entities. The gross margin is 56.5%, suggesting that the company retains a healthy portion of revenue after direct costs, although the operating margin of -583.0% and profit margin of 0.0% demonstrate that overhead costs are currently overwhelming operational efficiency. With cash reserves of $2.75M and zero debt, the balance sheet reflects a conservative stance with no leverage, effectively eliminating interest obligations but necessitating reliance on cash on hand or external financing to sustain operations. The current ratio of 1.43 indicates that the company possesses sufficient liquid assets to cover its short-term liabilities, providing a buffer against immediate liquidity crises despite the ongoing negative cash flow. Return on Equity is -547.6% and return on assets is -70.9%, metrics that reveal management is currently deploying capital to generate losses rather than profits, a common characteristic in pre-revenue or low-revenue stages of high-growth technology companies.
मूल्यांकन आकलन
The trailing P/E ratio and forward P/E ratio are both N/A due to the company's lack of positive earnings, meaning traditional earnings-based valuation multiples are inapplicable and investors must rely on alternative metrics to assess value. The price-to-book ratio is 3.13, which indicates that the market is valuing the company at a premium of roughly three times its book value, reflecting high expectations for future asset appreciation or intangible value not captured on the balance sheet. The price-to-sales ratio is 23.53 and the EV/EBITDA is -2.66, suggesting that the market is pricing the stock significantly based on top-line revenue potential rather than current profitability or cash generation capabilities. The stock has traded between a 52-week low of $0.62 and a 52-week high of $4.51, meaning the current price sits within a wide volatility range that has seen substantial movement, though the exact current price percentage relative to the high cannot be calculated without the real-time quote, but the range itself demonstrates significant price discovery activity. The beta value is N/A, which prevents a direct comparison of price volatility relative to the broader market, implying that the stock's price movements are driven primarily by company-specific factors or sector trends rather than general market fluctuations.
Growth & Income
Revenue growth year-over-year is 677.4%, while earnings growth is N/A due to the absence of positive earnings, indicating that the company is experiencing rapid top-line expansion before realizing corresponding profitability. Since the company is not a dividend payer, there is no dividend yield or payout ratio to analyze, and the payout ratio is 0.0%, which confirms that all available earnings, if any, are retained for reinvestment into the business rather than distributed to shareholders. This reinvestment strategy is typical for companies in the growth phase, where capital is directed toward scaling the Brain Network Analytics platform and advancing research into neuroscientific solutions rather than providing income to investors. The overall growth and income profile reflects a high-risk, high-reward trajectory where substantial revenue acceleration is occurring without current earnings support, requiring continuous capital infusion to bridge the gap to profitability.